Death-associated protein kinase (DAPK3) is a serine/threonine kinase involved in various signaling pathways important to tissue homeostasis and mammalian biology. Considered to be a putative tumor suppressor, the molecular mechanism by which DAPK3 exerts its suppressive function is not fully understood and the field lacks an appropriate mouse model. To address these gaps, an in vitro 3D tumorigenesis model was used and a constitutive DAPK3 knockout mouse was generated. In the 3D morphogenesis model, loss of DAPK3 through lentiviral-mediated knockdown enlarged acinar size by accelerated acini proliferation and apoptosis while maintaining acini polarity. Depletion of DAPK3 enhanced growth factor-dependent mTOR activation and, furthermore, enlarged DAPK3 acini structures were uniquely sensitive to low doses of rapamycin. Simultaneous knockdown of RAPTOR, a key mTORC1 component, reversed the augmented acinar size in DAPK3-depleted structures indicating an epistatic interaction. Utilizing a validated gene trap strategy to generate a constitutive DAPK3 knockout mouse, it was demonstrated that DAPK3 is vital for early mouse development. The Dapk3 promoter exhibits spatio-temporal activity in developing mice and is actively expressed in normal breast epithelia of adult mice. Importantly, reduction of DAPK3 expression correlates with the development of DCIS and more aggressive breast cancer as observed in the Oncomine database of clinical breast cancer specimens.
INTRODUCTION
Death-associated protein kinase 3 (DAPK3 or ZIPK) is a member of the DAPK serine/ threonine protein kinase family and is known to regulate smooth muscle contraction, cell-cell adhesion, cytoskeleton dynamics, inflammation as well as cardiovascular functions and is thought to serve as a tumor suppressor through regulation of caspase-dependent andindependent apoptosis, proliferation and autophagy (1) . The DAPK family contains 4 additional members, including DAPK1 (herein referred to as DAPK), DAPK2 (also DAPK-related protein 1), DRAK-1 and DRAK-2 (DAPK-related apoptosis-inducing protein kinase-1 and -2), which all share homology within their kinase domain. DAPK3 contains an N-terminal kinase domain that shares 80% amino acid homology with the prototypical DAPK, and differs from other family members by the presence of a C-terminal leucine zipper motif and absence of calmodulinregulated (CaM) and death domains.
Similar to other family members, DAPK3 is considered to be a tumor suppressor.
Overexpression of DAPK3 in mammalian cells results in cell death and cell cycle inhibition, while kinase inactivating mutations along with recurrent deleterious somatic mutations are observed in lung and breast cancers, respectively (2) (3) (4) . Knockdown of DAPK3 increases proliferation of various cell lines (2) . Clinically, reduced DAPK3 mRNA correlates with increased tumor invasion, metastasis and overall survival in gastric carcinoma patients (5) .
Abrogation of DAPK3 mRNA expression was shown to significantly decrease cisplatin sensitivity in various lung cancer cell lines and may impact overall survival of non-small cell lung cancer patients treated with platinum-based therapy (6) . DAPK3 is also considered a potentially novel breast cancer gene as recurrent DAPK3 alterations were observed in both BRCA1 mutant and non-mutant breast cancers (3) . Additionally, human DAPK3 regulates a 4 variety of signaling pathways commonly deregulated in cancer. For example, DAPK3 negatively regulates the canonical Wnt/ β-catenin pathway by disrupting the interaction between Nemo-like kinase and T-cell Factor 4 in colon cancer cell lines (7) . It also regulates androgen receptormediated transcription via ubiquitination and degradation of androgen receptor in various cancer cell lines (8) . DAPK3 also interacts with and/ or phosphorylates various cancer-associated proteins in vitro, including ATF4, AATF, Daxx, Par-4 and STAT-3 (4, (9) (10) (11) (12) .
Despite these in vitro and clinical observations, the full physiological significance of DAPK3 is not well understood. Additionally, compared to the prototypical DAPK family member DAPK, relatively little is known about the functional tumor suppressive mechanisms regulated by DAPK3. These limitations are potentially exacerbated by the lack of a knockout mouse model as well as inadequate cell culture models that cannot recapitulate the physiological context of tissue development or carcinogenesis. Three-dimensional (3D) in vitro tumor systems provide the ability to functionally investigate the contribution of tumor suppressors and oncogenes to the complex development and architecture of tumor spheroids (13) . Given the utility of 3D tumor systems and the clinically observed mutations of DAPK3 in breast cancer (3), we chose to further explore the functional significance of DAPK3 in a MCF10A 3D morphogenesis model. When grown on an extracellular enriched matrix (Matrigel), the immortalized MCF10A epithelial cell line forms hollow spheroids that undergo a regulated and coordinated series of biochemical and phenotypic events (14). This model has been used to investigate the contribution of loss-of-function (LOF) alterations to acini development and early events in tumor formation.
Herein, we describe the functional significance of DAPK3 in MCF10A acini morphogenesis and characterize the early lethality observed in a DAPK3 knockout mouse. We 
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identified that DAPK3 negatively regulates MCF10A morphogenesis through a mTORC1/S6 pathway that is independent of enhanced AKT and ERK signaling. Our studies also shed light on an unexpected role for DAPK3 in mouse development as well as a spatially distinct expression pattern with potential relevancy to human development and breast cancer. We also identified that DAPK3 is downregulated in aggressive breast cancer relative to less aggressive and normal patient samples.
MATERIALS & METHODS
Cell culture and reagents. MCF10A and 293T cells were obtained directly from the American Type Culture Collection in 2011 and not further tested. MCF10A cells were cultured as previously described (14) and 293T were cultured in DMEM supplemented with 10%FBS and Lglutamine. 3D morphogenesis assays were conducted as previously described (14). Inhibitors: LY294002 (Cell Signaling, 9901), rapamycin (Sigma-Aldrich, R8781).
Plasmids viral production, and lentiviral transduction. For DAPK3 overexpression, the DAPK3 ORF was PCR amplified (from Addgene plasmid 23436) and subcloned into pLVX- 293T cells were co-transfected with pCMV-VSV-G, pCMVΔR8.2, and pLKO.1-puro constructs using Fugene 6 (Promega). Forty-eight hours post-transfection, viral supernatants were collected. MCF10A were subsequently incubated for 8 hours with filtered viral supernatants after which fresh media was added. The following day the media was replaced with a second round of viral supernatant after which fresh media was added for 24 hours. Stable cells were then selected using 1 µg/ mL puromycin for two passages. Stable cells were then allowed to recover from selection for one passage prior to use in 2D and 3D assays. For 2D assays, stable cells were plated at an equal density such that they would be ~75% confluent at initiation of the experiment. PLKO.1-hygro shRNA constructs against RICTOR and RAPTOR were generated by subcloning hygromycin in place of puromycin within the pLKO.1-constructs and similarly selected using 500 µg/ mL hygromycin. For double knockdown, MCF10A were simultaneously infected with both appropriate shRNA-puromycin (shRNA P ) and shRNAhygromycin (shRNA H ) virus and subsequently selected with both 1 µg/ mL puromycin and 500 µg/ mL hygromycin for one passage followed by one passage in normal media.
IRES
Immunofluorescence and confocal microscopy. 
RESULTS

DAPK3 depletion augments acini morphogenesis.
To investigate mechanisms by which DAPK3 exerts tumor suppressive functions, we performed stable shRNA knockdown of DAPK3 in MCF10A cells grown on Matrigel using two independent hairpins. As discussed previously, this model permits interrogation of acini architecture development, which undergoes a series of highly conserved temporally-concerted biochemical and phenotypic events. Loss of DAPK3 significantly enhanced acini diameter by approximately 37+10 % as compared to negative control shRNA at day 8 ( Figure 1A 
Loss of DAPK3 results in enhanced acini proliferation and apoptosis.
It has been well established that size and morphogenesis of MCF10A acini are dependent on coordinated proliferation and apoptotic programs. To understand which of these processes was perturbed in DAPK3 knockdown structures, we performed confocal immunofluorescence microscopy on acini structures. DAPK3-depleted structures contained, on average, significantly more cells positive for expression of the proliferation marker Ki67, compared to negative control (Figure 2A) . Interestingly, loss of DAPK3 also significantly increased the number of acini containing cells positive for apoptosis as visualized by cleaved caspase 3, relative to negative control ( Figure 2B ). This was additionally confirmed by ethidium bromide uptake in live MCF10A acini, which also indicated an increase in cell death in DAPK3-depleted structures (Suppl. Figure 2) . Thus, while there was a net increase in acinar size, we hypothesize that as the shDAPK3 structures underwent hyperproliferation, more cells lost contact with the ECM and as a result underwent apoptosis, a phenomenon which has been observed elsewhere (17) . 
DAPK3 overexpression disrupts normal acini formation.
To determine if DAPK3 overexpression impacts acinar morphogenesis, we stably overexpressed DAPK3 fused to GFP in MCF10A cells that were subsequently grown in 3D culture. Despite a large degree of toxicity observed in the packaging cells used to generate viral particles, we were able to achieve stable populations of MCF10A cells that survived selection. However, we were not able to achieve high overexpression of DAPK3 most likely due to overexpression toxicities in both target and packaging cells, which has been commonly observed across several cell types (2, 18) . Additionally, this expression was lost over time indicating negative selection for sustained high level expression of DAPK3. Despite these technical challenges, MCF10A structures that maintained overexpression (as indicated by GFP fluorescence) displayed a dramatic and significant decrease in structure size compared to empty-GFP vector alone (Figure 3A, B) . We also attempted to determine if this decrease in size was dependent on DAPK3 kinase activity but we were unable to achieve stable overexpression of a previously characterized kinase-deficient point mutant (K42A) fused to GFP (data not shown).
However, confirmed stable overexpression of an unfused K42A mutant exhibited microscopic colony growth in soft agar highly similar to negative control, while a significant decrease was observed in stable cells overexpressing wildtype DAPK3 (Suppl. Figure 3A) , consistent with growth inhibition dependent on kinase activity. We confirmed the signaling competency of overexpressed FLAG tagged DAPK3 in 293T cells. Specifically, transient overexpression of DAPK3 increased MLC-2 phosphorylation compared to K42A and empty vector (Suppl. Figure   3B ). DAPK3 negatively regulates mTOR-S6K-S6 signaling with no effect on ERK or AKT activation. 
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To identify the pathways regulated by DAPK3 in this context, we initially compared our acini phenotypes to those of previous reports. Several groups have shown that enhanced mTOR activity leads to acini with abnormalities similar to those observed upon loss of DAPK3 (19) (20) (21) .
Indeed, knockdown of DAPK3 in MCF10A cells grown in 2D culture resulted in increased phosphorylation of S6 (P-S6) and both S6K isoforms (herein referred to as P-S6K) when stimulated with EGF or insulin ( Figure 4A) . We additionally observed an increase in P-S6 from MCF10A cells depleted of DAPK3 and grown in 3D culture for 6 days ( Figure 4B) . Of note, in 2D and 3D experiments, we did not observe a concomitant increase in the activation of ERK or AKT signaling (Suppl. Figure 4) , which are upstream regulators of mTOR signaling (22) .
Loss of DAPK3 influences proper acini morphogenesis through mTORC1.
To further confirm that the observed increase in S6 signaling was functionally relevant, we treated established negative control and DAPK3-depleted acini with 100 nM rapamycin once at day 4. Then, 4 days later, we observed that rapamycin had no significant effect on the diameter of the negative control. However, acini stably transduced with DAPK3 hairpins displayed a significant sensitivity to rapamycin treatment, showing a statistically significant decrease in acini diameter relative to no treatment ( Figure 5A) . Additionally, established shDAPK3 acini treated with increasing concentrations (100 nM, 10 µM and 50 µM) of the PI3K and mTOR inhibitor LY294002 displayed similar increased sensitivity to the drug compared to negative control ( Figure 5B ).
To further delineate how DAPK3 regulates mTOR for proper acini morphogenesis, we stably knocked down DAPK3 and RICTOR or RAPTOR concurrently using previously reported hairpins (23) . The mTOR catalytic subunit is shared between two distinct mTOR complexes, 
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mTORC1 and mTORC2, which elicit the variety of functions of the mTOR pathway (22) .
Regulatory-associated protein of mammalian target of rapamycin (RAPTOR) and rapamycininsensitive companion of mTOR (RICTOR) are necessary components of the mTOR complexes comprising mTORC1 and mTORC2, respectively. Interestingly, we observed that concurrent loss of DAPK3 and RAPTOR blunted the increased acini size observed with DAPK3 depletion alone, whereas concurrent loss of RICTOR did not rescue the phenotype ( Figure 5C ).
Additionally, loss of RAPTOR by itself had a profound impact on acini formation whereas knockdown of RICTOR did not.
These results identify an epistatic interaction between DAPK3 and the mTORC1 pathway with functional consequences through regulation of S6K-S6 signaling and potentially other downstream mTORC1 effectors ( Figure 5D ).
Generation and characterization of embryonic lethality in DAPK3 null mice.
In an attempt to understand the in vivo contribution of DAPK3 to mouse mammary development, its overall role in mouse development, and DAPK3-specific oncologic recapitulations of ontogeny, we created a constitutive DAPK3 knockout mouse using a preconfirmed gene trap ES cell line from the International Gene Trap Consortium. As shown in Figure 6A , the gene trap (Gt) is composed of a 5' splice acceptor site (green) followed by a β galactosidase-neomycin fusion (βgeo) (blue) and a polyA tail (red). We further confirmed that the locus and the entire gene trap were intact and incorporated into genomic DNA as a single insertion through Southern blot analysis using both external probes and an internal probe ( Figure   6B ). Importantly, we determined that the gene trap integrated between the second and third exon.
These ES cells were then used to generate a mouse using conventional blastocyst injection and Figure 5 ).
Despite grossly healthy heterozygous adults, we were unable to identify any homozygous Gt/Gt (Dapk3 -/-) animals on a mixed 129Ola or backcrossed C57BL/6 (N5) background (Suppl.
Table 1).
We were also unable to locate homozygous Gt/Gt embryos at E12.5, E10.5, and E8.5, despite near Mendelian ratios for wild type and heterozygous embryos, indicating early homozygous lethality (Suppl. Table 1 ). This was further confirmed by the presence of several sites of fetal resorption on uteri extracted from heterozygous crosses versus heterozygous X wild type crosses ( Figure 6D) . However, note that we were able to isolate and genotype Gt/Gt homozygous blastocysts at E3.5 ( Figure 6C ), indicating that lethality was likely occurring postimplantation. Furthermore, there was no difference in distribution of homozygous embryos across blastocyst, morula and pre-morula stages (data not shown).
Early mouse embryonic and adult expression patterns of Dapk3.
Overall, heterozygous animals appeared to develop and grow normally with no overt phenotypes under standard laboratory conditions. Taking advantage of the functional βgal expressed under the endogenous Dapk3 promoter, we characterized the expression patterns of Dapk3 during the development of heterozygous mice. We observed distinct and strong βgal activity in the developing heart of E8.5 and E10.5 embryos (Figure 6E, top panel) .
Additionally, E10.5 heterozygous embryos displayed localized activity within the developing notochord ( Figure 6E, bottom panel) . As expected, no βgal activity was observed in developing wildtype littermates (data not shown). 
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Mouse breast epithelium expression and clinically observed down regulation of DAPK3.
To determine the potential utility of DAPK3 knockout mice for breast cancer studies we wanted to confirm Dapk3 expression in mouse mammary epithelium. Due to our inability to locate antibodies that could detect endogenous mouse DAPK3, we visualized Dapk3 expression using antibodies that recognized β-galactosidase/ LacZ as expressed from the gene trap downstream of the endogenous Dapk3 promoter. We observed strong and distinct staining in the mammary epithelium of heterozygous mouse mammary fat pads with no observable staining in wildtype littermate controls ( Figure 7A) . Finally, to confirm that our cell culture and murine observations mimic those seen in actual patients, we analyzed the Oncomine database However, loss of DAPK3 combined with loss of RAPTOR was able to significantly overcome the inhibition observed in RAPTOR knockdown alone. While this effect was statistically significant, it remains formally possible that an additional mechanism by which mTORC1/RAPTOR suppresses acini morphogenesis is independent of DAPK3 and further studies are necessary. Strikingly, DAPK3 is required for early mouse development post blastocyst implantation. Our studies also suggest that DAPK3 is expressed in mouse mammary epithelium and that downregulation correlates with neoplastic progression in breast cancer patients. Collectively, our data reveal a novel tumor suppressive mechanism for DAPK3 and highlight its fundamental requirement for mouse development.
It is well known that the mTOR pathway plays an important role in cancer cell growth, survival and proliferation (22) . mTOR is the fundamental catalytic component of two distinct 
complexes, rapamycin-sensitive mTORC1 and rapamycin insentitive-mTORC2, each of which is composed of distinct protein complexes that alter the protein-protein interactions, subcellular localization, activity and substrate specificity of the active complex. Genetic ablation of key scaffolding proteins RAPTOR or RICTOR effectively prevents signaling through mTORC1 and mTORC2, respectively. Activation of the mTOR pathway is controlled by several upstream tumor suppressors, including LKB1 and NF1 (24, 25) . Interestingly, several other member of the DAPK tumor suppressor family are known to regulate translation and regulate or be regulated by the mTOR pathway. Conflicting reports reveal that DAPK disrupts TSC1-TSC2 association, thereby enhancing mTOR activation, and negatively regulates protein translation through an inhibitory phosphorylation at S235/236 of S6 (26, 27) . However, Roux et al. revealed RSKdependent phosphorylation at S235/ 236 actually promotes translation through assembly of the translational pre-initiation complex (28) . DRAK2 phosphorylates S6K kinase in vitro and in vivo (29) . DAPK3 itself is phosphorylated by DAPK in vitro and this DAPK-DAPK3 kinase cascade has been shown to inhibit transcript-specific translation through phosphorylation of the ribosomal protein L13a and activation of an translational inhibitor complex known as the IFNgamma-activated inhibitor of translation (GAIT) complex (18, 30) . Further work is required to specifically determine how DAPK3 negatively regulates mTOR-S6K-S6 signaling. We hypothesize that DAPK3 can directly or indirectly inhibit mTORC1 signaling upstream of S6 or it may directly influence S6K or S6 similar to other DAPK family members. Overall, our data provide further evidence to indicate that DAPK family members are important regulators of translation and mTOR signaling.
Moreover, through the generation and characterization of a DAPK3 knockout mouse, our data reveal that DAPK3 is crucial to early mouse development. Our analysis indicates that 
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DAPK3-deficient blastocysts are able to implant, but subsequent development is problematic. At this point in mouse embryonic development (E4.5-E6.5), various embryonic germ layers undergo differentiation, migration and establishment of early morphologic axes (31) . DAPK3 is known to regulate cellular migration and contraction and thus, DAPK3 may be crucial for these early developmental events (32, 33) . Remarkably, embryonic lethality was not anticipated given that Dapk -/-mice develop normally as indicated by their overall basal health (34) . This dichotomy raises a number of questions regarding signaling redundancies between DAPK and DAPK3 and highlights important developmental functions for DAPK3. Our data support the need for future development of conditional DAPK3 knockout mice, which may serve as relevant models for interrogating tumor suppressive mechanisms for DAPK3 in mouse models of breast cancer.
However, it is worth noting potential functional differences between human and murine DAPK3.
Specifically, murine DAPK3 exhibits C-terminal amino acid substitutions that may impart differential signaling patterns or tumor suppressive signaling mechanisms not seen in human systems (35) . Nonetheless, our work identified that mouse DAPK3 exhibits localized expression in the developing heart and nervous system, and these expression patterns and developmental observations are of potential relevance to humans. Specifically, DAPK3 resides on chromosome 
